Hjem › Sklerodermi › Illinois
Sklerodermi kliniske forsøg i Illinois
11 studier for Sklerodermi søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RekruttererFase 1
Alder 18 til 70 · Alle køn · Opdateret 28. aug. 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RekruttererFase 2/3
Alder 18 til 75 · Alle køn · Opdateret 17. aug. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2025 · NCT05892614Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.